still busi issu sort noth thesi chang
valuat start get silli
thursday even februari report fiscal first-quart result
updat fiscal guidanc result top line consist pre-releas
earli januari show revenu million report organ
fx neutral fxn estim million guidanc
million upsid versu model came cytolog million
blood screen million breast imag million intervent breast
million skin million shortfal versu model came molecular diagnost
million bodi aesthet million gyn surgic million
revenu core busi ex cynosur blood screen
major highlight contribut new product revenu ep
well guidanc rang larg result tax benefit
respect guidanc bit disappoint rel second-quart
commentari call sequenti slow first quarter due combin
non-core blood screen order compani partner season surgic
medic aesthet expect weaker revenu diagnost due
weather trend two larg refer lab cite call labcorp lh
outperform quest market perform larg custom
though seem like stretch us addit surgic busi like get bit
wors get better still inflect expect medic aesthet
easi would like earn side compani intend take half
benefit lower tax rate bottom line year though suspect
flexibl number term time fund addit project know team
well suspect left plenti cushion bottom line consid
tax implic
model bit weight fourth quarter expect
improv medic aesthet year new product launch grow foreign-
exchang benefit full year still seem achiev though paint upsid case
return equiti ttm
develop manufactur medic imag system product emphasi women health
busi unit focus breast health diagnost gynecolog surgeri aesthet skelet health
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
net-net quarter seem unlik chang anyon broader thesi stock though bring increment
question full-year target despit posit momentum oversea doubl digit fourth straight quarter good
number breast stabl perform diagnost still uncertainti around pace turnaround medic
aesthet consensu number busi may prove high surgic seem
pressur expect
still support guidanc rang top bottom line year though deni lower
second-quart guidanc make longer put contribut new revenu year progress margin
improv opportun realist chanc tuck-in revenu think surgic boost lower tax rate give
compani room bottom line remain enough like stori continu recommend stock
discount valuat long-term averag current valuat time forward four-quart ep
estim versu histor averag time free cash flow yield least believ
disconnect stock long-term opportun financi outlook compani
medic aesthet still gear much better result versu expect seen prior three
quarter medic aesthet busi still seem remain stuck mud somewher swamp jersey
doubt signific amount progress made improv talent cultur train product
revenu yet follow suit seen sculpsur busi sequenti typic
look ahead manag seem wishy-washi abil grow sequenti fiscal second quarter though
see sequenti focu myopic way think situat whether busi million flat
sequenti million million realli neither think result rang
expect million full year second half year need signific acceler
recent trend line mean get answer summer june quarter announc major
step-up need rethink view busi
fortun issu product franchis competit recent addit
subment claim sculpsur innov way rf launch combin hungrier
salesforc profession manag lot cash thrown fix problem remain cautious optimist
need inflect occur
thought breast imag show second straight quarter good perform new product breast imag
intervent help overal perform revenu segment four fewer sell
day someth continu expect number somewher domest
point still expect vast major system convert technolog believ remain
domin player still gain share essenti still signific runway ahead convers
 say noth massiv share gain opportun outsid expect materi come
diagnost recent trend continu panther instrument gain nice momentum world-wide util per
panther run room move toward base new assay introduc
state recent note pleasantli surpris interest compani panther fusion product
wit variou industri tradeshow year addit panther give lead women
health platform ct/ng trichomona vaginali hpv hpv genotyp full suit virolog target hcv
hbv respiratori test solut includ smaller plex-siz flu a/b/rsv adenovirus/human
metapneumovirus/rhinoviru paraflu may benefici consid reimburs concern larger
respiratori panel outpati panel expect menu expans along intern expans abl
drive high-single-digit growth molecular diagnost next coupl year
surgic latest area manag need put fire perform slow
long run myosur growth better multi-quart benefit ablat novasur competit
recal howev myosur later inning growth trajectori still solid level seen
previous increment competit pressur novasur manag use tri true formula
turnaround bring new leadership hire new sale rep ad new product order spur growth
would surpris addit product ad bag next year though manag quit
clear perform exist two product need better seen late
quarter reviewcurr actualcurr estimateprior year quarter thousand unless profit ep better expect due taxservic ep bridg estim sale volum oper expens income/expens incom tax total ep beat estim income/ expens earn incom tax effect net incom dilut share ep compani report william blair compani estimatesconsensu estim currentrevenu earn per factset consensusfav/ unfav variancefav/ unfav varianc william blair
revenu review segment current actualcurr estim thousand unless commentari revenu segment report diagnosticscytolog continu strengthen share cytolog saw higher sale perinat expectedmolecular constant currenc driven strength aptima product worldwideblood overal breast segment y/ybreast us declin due tough comp expect /- go forwardintervent breast ou grew second quarter growth breast line expect bodi continu struggl increment nvestment madegyn fxn myosur increas novasur latest fire management need addressskelet due lower sale fluoroscan productstot compani report william blair compani estimateschang model thousand unless notedprevi estimatechangecurr updat guidanceprevi estimatechangecurr revenu estim reduc due lower remain within guidanc fxn growth msd organ fxn gross major chang due lower estim margin product bp bp cynosur surgic off-set oper stronger breast revenuesoper gross margin expect expand roughli bp bp oper expens increas manag plan spendoth income/ expens approxim half tax benfit market projectsearn total tax benefit approxim million vs prior modelincom tax share count guidanc reduc effect bp bp net incom bp bp dilut share ep growth/ declin yoy ep revenu chang report previouschangecurr growth come menu expans panther placement continu strength ou growth near struggl continu novasur underperform pro forma growth well manag compani report william blair compani import disclosur
